Neeman Medical International is part of a global study enrolling patients with Advanced or Metastatic Breast Cancer with ErbB2 Fluorescence in Situ Hybridization (FISH) positive tumors. This study is presently undergoing enrollment in 14 countries globally with a target of 140 patients.

In India there are a total of 8 sites of which Neeman is managing 3 sites.

For more details on the study, please visit:

http://clinicaltrials-nccs.nlm.nih.gov/ct/show/NCT00347919?order=2